Table 1.
Summary of lncRNAs diseases with disturbed cholesterol homeostasis.
| lncRNAs | Target genes | Function | Diseases | References |
|---|---|---|---|---|
| Cholesterol efflux | ||||
| CDKN2B-AS1 | ADAM10 | cholesterol efflux (+) | Atherosclerosis | (34) |
| CHROME | miR-27b, miR-33a/b and miR-128 | Cholesterol efflux (+) | CAD | (35) |
| ENST00000602558.1 | p65 | Cholesterol efflux (+) | CAD | (36) |
| MALAT1 | SREBP-1c | Cholesterol efflux (+) | Hepatic steatosis and insulin resistance | (31) |
| Lipid accumulation | ||||
| GAS5 | miR-135a | Lipid accumulation (+) | Atherosclerosis | (37) |
| MEG3 | miR-21 | Lipid accumulation (+) | NAFLD | (38) |
| H19 | MLXIPL and mTORC1 | Lipid accumulation (+) | NAFLD | (39) |
| MALAT1 | miR-17-5p | Lipid accumulation (+) | Atherosclerosis | (40) |
| HOXC-AS1 | HOXC6 | Lipid accumulation (+) | Atherosclerosis | (41) |
| HOTAIR | NF-κB | Lipid accumulation (+) | Atherosclerosis | (42) |
| NEAT1 | miR-146a-5p | Lipid accumulation (+) | NAFLD | (43) |
| Lipid metabolism | ||||
| Lnc-HC | miR-130b-3p | Lipid metabolism (+) | NAFLD | (44) |
| ENST00000416361 | SREBP1, SREBP2 | Lipid metabolism (+) | CAD | (45) |
| LeXis | RALY | Lipid metabolism (−) | – | (46) |
| Lipid desaturation | ||||
| LINC01138 | PRMT5 | Lipid desaturation (+) | Kidney malignancy | (47) |
| HDL-C and LDL-C level | ||||
| SNHG17 | – | HDL-C level (−) | Type 2 diabetes mellitus | (48) |
| TTC28-AS1 | – | LDL-C level (+) | Type 2 diabetes mellitus | (48) |
| MIAT | HIF1α, ALKBH1 | LDL-C level (+) | Atherosclerosis | (49) |
| LINC00958 | miR-382-5p | HDL-C (+) and LDL-C level (−) | Atherosclerosis | (50) |
| Hepatic lipogenesis | ||||
| LINC00958 | miR-3619-5p | Hepatic lipogenesis (+) | HCC | (51) |
| Blnc1 | SREBP1c | Hepatic lipogenesis | Obesity and NAFLD | (20) |